RankAlpha logo
Back to Rankings

MBRX

Moleculin BiotechF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
MIRACLE's preliminary efficacy signal could drive a substantial re-rating if confirmed in the full study, while the $9.3 million gross financing provides capital for development. The upside remains highly conditional because the company also states that significant additional financing is required.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Interim efficacy results were based on 45 patients, had not achieved statistical significance, and may not predict the completed trial [#PR-EARNINGS-2026-07-06].
Momentum
67
Value
41
Sentiment
16
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.52 · Bull $1.05 · Bear $0.20Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-10

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum67 · Δ7d -
Value41 · Δ7d -0.0
Sentiment16 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • • Interim efficacy results were based on 45 patients, had not achieved statistical significance, and may not predict the completed trial [#PR-EARNINGS-2026-07-06].
  • • Post-earnings consensus surprise data, analyst revisions, and verified market-reaction attribution are unavailable; coverage is low and no direct operating peers were established.
  • • The interim dataset is small and not statistically significant, and secondary coverage described the trial update negatively [#SERP-1].

Catalyst clock

2026-11-11

Further MIRACLE efficacy disclosure

Lead driver: Value · See fundamentals
Momentum
67
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
16
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 67.2 / Value 41.2 / Sentiment 15.9

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method

B+
Bull case
20%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.52
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.82M
Beta
1.64
Shares Out
7.1M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.18
Rev YoY
-
EPS YoY
-95.1%
Gross Margin
-
Op Margin
-
Net Debt
-$8.52M
Current Ratio
0.94
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data